Press Releases 2002

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sabinsa Wins ForsLean® Patent Infringement Suit Against Indfrag Ltd.

Sabinsa Develops L-(+)-Selenomethionine HPLC Assay Procedure, Shares Method With Analytical Labs

Sabinsa Corporation Announces The Development of A New Drug to Fight African Sleeping Sickness

ABOUT SAMI LABS

HEADQUARTERS

CERTIFICATES

CONTACT US